With the deepening understanding of various retinal diseases, intravitreal injection (IVI) has gradually become a first-line treatment for multiple retinal conditions, and its clinical application has shown rapid growth. Against the backdrop of continuous advancements in new anti-vascular endothelial growth factor agents and corticosteroid implants, as well as the accumulation of clinical evidence, IVI faces new challenges in various aspects. These include perioperative disinfection and anesthesia, storage and handling of injection drugs, individualized dose adjustment, standardized injection procedures, prevention and management of postoperative adverse events, and comprehensive patient management throughout the treatment process. To standardize clinical practice, enhance medical quality, and ensure patient safety, Fundus Disease Group of Ophthalmological Society of Chinese Medical Association, Fundus Disease Group of Ophthalmologist Branch of Chinese Medical Doctor Association, in collaboration with Expert Group of Chinese Expert Consensus on Quality Control for Intravitreal Injections (2026), after systematically reviewing the latest evidence-based medical data, referring to relevant international guidelines, and fully considering the current clinical practice situation in China, conducted in-depth discussions on eight key clinical issues related to IVI. This work was based on a systematic review of the latest evidence-based medical literature, international guidelines, and a thorough consideration of the current clinical practice in China. The quality control standard for intravitreal injections for fundus diseases in China (2015) has been comprehensively revised, resulting in the formulation of this quality control standard. This standard aims to provide standardized operational protocols for IVI to ophthalmologists and retinal specialists, offer evidence-based support for key clinical decisions, improve the quality management system for IVI in China, and effectively ensure patient treatment safety and efficacy.